Curatis Holding AG Reports Strong Half-Year Growth and Advances in C-PTBE-01

Curatis Holding AG experienced its most robust half-year performance, with a 51% increase in revenue, reaching CHF 7.9 million in H1 2026. The loss narrowed to CHF -0.4 million from CHF -1.2 million the previous year. Cash reserves increased to CHF 3.6 million, partly due to a CHF 3.0 million investment converted into equity.

The company made significant strides in the development of its lead product candidate, corticorelin (C-PTBE-01). An exclusive licensing agreement with Neupharma in Japan, valued at up to CHF 83.5 million, was a notable achievement. Progress in manufacturing and technical development remained on track.

Curatis anticipates reaching a break-even result in 2026, projecting revenues of approximately CHF 15 million for the year. Plans to meet the FDA in early 2027 to finalize clinical study designs signal continued commitment to their innovative objectives.